NEXUS

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Research, Ulcerative colitis, ECCO, LTE, ACG, Patient, UC, Journal, Biomarker, NEXUS, Wind, Insurance, Abstract, American College, Clinical trial, Safety, Pharmacokinetics, Poster, NLRX1, European, PLXDC2, Pharmaceutical industry

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.
  • Top-line results are planned for the fourth quarter of 2024.
  • Research and development expenses were $3.1 million for the fourth quarter of 2023, compared to $3.4 million for the fourth quarter of 2022.
  • General and administrative expenses were $3.5 million for the fourth quarter of 2023, compared to $3.1 million for the fourth quarter of 2022.

The CBSA and U.S. CBP provide an update on the NEXUS program

Retrieved on: 
Tuesday, April 2, 2024
Telephone, Transport, CBSA, Introduction, Interview, Crime, NEXUS, CBP, Airport, Canada Border Services Agency, Television

The current fee, set over 20 years ago, no longer covers the cost of the program.

Key Points: 
  • The current fee, set over 20 years ago, no longer covers the cost of the program.
  • The new fee would reflect more accurately the cost of administrating the program and the investment required for future program improvements, including technology and infrastructure enhancements.
  • The proposed increase would help keep up with the high demand for the program and continue to improve NEXUS.
  • The NEXUS program currently has over 1.8 million members, with the majority of members being Canadian.

NEXEN TIRE awarded two main prizes at iF Design Awards 2024

Retrieved on: 
Tuesday, March 5, 2024
Nexen Tire, Sejong University, Communication, NEXUS, History, Movement, Student

SEOUL, South Korea, March 05, 2024 (GLOBE NEWSWIRE) -- NEXEN TIRE, a leading global tire manufacturer, today announced that two works, NEXERA and NEXUS, have won the main prize in the communication design category of Germany's iF Design Awards 2024.

Key Points: 
  • SEOUL, South Korea, March 05, 2024 (GLOBE NEWSWIRE) -- NEXEN TIRE, a leading global tire manufacturer, today announced that two works, NEXERA and NEXUS, have won the main prize in the communication design category of Germany's iF Design Awards 2024.
  • The works awarded by NEXEN Tire are the result of an industry-academic collaboration with Sejong University and its students from the design innovation major.
  • The visual design works that have been reinterpreted and released are based on NEXEN Tire's design philosophy, "Ultimate Sensual, Timeless Movement."
  • The iF International Forum Design GmbH is a long-standing independent design organization based in Hanover, Germany, that annually awards the iF Design Award for the best design results.

PEI Group Unveils NEXUS 2024: The Premier Private Investment Summit

Retrieved on: 
Monday, February 12, 2024
Senior, Intelligence, GP, Golf, Private Equity International, The Carlyle Group, Orlando Bravo, Oaktree Capital Management, CalSTRS, NEXUS, LP record, Partner (business rank), Thoma Bravo, Publication, PEI

NEW YORK, Feb. 12, 2024 /PRNewswire-PRWeb/ -- PEI Group, the leading source of intelligence for the private investment industry, is pleased to announce NEXUS 2024, the inaugural installment of an annual summit that aims to recast the conversation around and within private equity and connect limited partners responsible for more than $30 trillion with top-tier general partners.

Key Points: 
  • "With over 500 influential participants, including top investors, managers, and service providers in the asset class, NEXUS 2024 is a must-attend event for anyone in the private equity industry," said William O'Conor, PEI's U.S.
  • NEXUS 2024, which takes place March 6-8, 2024, in Orlando, Florida, is supported by three key industry publications published by PEI Group: Buyouts , the leading authority in U.S. mid-market private equity; PE Hub , the premium intelligence service covering private equity deal-making in North America, and Private Equity International , the only global publication with a primary focus on the relationship between private equity investors and fund managers.
  • The event is a natural extension of PEI Group's commitment to advancing the broad private equity community.
  • "2024 represents a pivotal year for private equity, and investors are at a critical juncture with respect to allocations and emerging opportunities.

Dealer Alchemist Announces Strategic Acquisition of AutoGo to Enhance its Automotive Digital Solutions

Retrieved on: 
Thursday, February 1, 2024
NEXUS, Advertising, Ecosystem, Marketing, Acquisition, Car dealership

LONE TREE, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dealer Alchemist , a pioneer in automotive marketing solutions, is thrilled to announce the acquisition of AutoGo (formerly Dealer Venom), a leader in advanced automotive website platforms.

Key Points: 
  • LONE TREE, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dealer Alchemist , a pioneer in automotive marketing solutions, is thrilled to announce the acquisition of AutoGo (formerly Dealer Venom), a leader in advanced automotive website platforms.
  • This acquisition marks a significant milestone in Dealer Alchemist's mission to revolutionize digital advertising in the automotive industry.
  • This combined platform will now be a pivotal offering for Dealer Alchemist and AutoGo clients, promising to elevate their digital presence and operational effectiveness.
  • "This acquisition is a game-changer for Dealer Alchemist and our dealers," said Shean Kirin, CEO of Dealer Alchemist.

Endospan Releases Early TRIOMPHE IDE Study Results at Society of Thoracic Surgeons

Retrieved on: 
Tuesday, January 30, 2024
Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, General Health, Oncology, Multimedia, ICU, Surgeon, Mortality, Hypothermia, Trial of the century, Kidney, Disease, NEXUS, Society, Patient, Safety, Hospital, Paraplegia, IDE

As a notice of availability to educate potential referring physicians about the TRIOMPHE study, Endospan shared the 30-day results of the first 22 patients enrolled in the TRIOMPHE IDE study in a Late-Breaking presentation at the 60th Annual Meeting of the Society of Thoracic Surgeons in San Antonio, Texas this past weekend.

Key Points: 
  • As a notice of availability to educate potential referring physicians about the TRIOMPHE study, Endospan shared the 30-day results of the first 22 patients enrolled in the TRIOMPHE IDE study in a Late-Breaking presentation at the 60th Annual Meeting of the Society of Thoracic Surgeons in San Antonio, Texas this past weekend.
  • TRIOMPHE is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS® in treating thoracic aortic lesions involving the aortic arch.
  • “NEXUS is designed for total endovascular arch repair to address the specific challenges of the aortic arch anatomy,” said Kevin Mayberry, CEO.
  • “We are pleased to see that this early data aligns with the results achieved during the EU clinical study.

AAMI and FDA Co-Sponsor Medtech Conference, ‘AAMI and FDA neXus'

Retrieved on: 
Monday, January 8, 2024
Nexus, Conference, University of Utah, Food, Johnson & Johnson, FDA, NEXUS, ISC, QSR, AAMI, ASCA, University, Omni Shoreham Hotel, Sterilization, Device, CDRH, Ethylene oxide, ISO, USB On-The-Go, Intuitive Surgical, Medical device

The conference will feature a wealth of FDA experts alongside industry members and will focus on the latest information on medical device regulations and standards.

Key Points: 
  • The conference will feature a wealth of FDA experts alongside industry members and will focus on the latest information on medical device regulations and standards.
  • Real-world evidence and medical device safety, presented by Daniel Caños, director of the Office of Clinical Evidence and Analysis at CDRH.
  • The FDA case for quality, delivered by Francisco Vicenty, FDA consumer safety officer.
  • Development, adoption, and now application of standards, neXus covers it all.”
    Those interested in attending can find registration for the AAMI FDA neXus here .

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024
Human, Treatment, Chronic pain, Homeostasis, PLXDC2, Ulcer, Disease, UC, Doctor of Philosophy, ECCO, Pharmacokinetics, NLRX1, Abstract, UZ Leuven, Library, Congress, European, Effect, Inflammatory Bowel Diseases, Inflammation, Patient, Translation, Immunometabolism, Safety, Landos, NEXUS, Pharmaceutical industry

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

Retrieved on: 
Tuesday, November 21, 2023
Pharmacokinetics, NLRX1, Patient, Landos, NEXUS, Journal, Ulcerative colitis, Pharmaceutical industry

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a peer-reviewed publication describing the safety, tolerability, pharmacokinetic and clinical efficacy results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC) in the Journal of Crohn’s and Colitis.

Key Points: 
  • “We are delighted to have our Phase 1b results of NX-13 in UC published in the Journal of Crohn’s and Colitis,” said Dr. Fabio Cataldi, Executive Vice-President & Chief Medical Officer at Landos.
  • NX-13 was found to be well tolerated in all patients studied.
  • No deaths or severe adverse events were reported and all adverse events were mild to moderate.
  • “The early signs of efficacy, along with a favorable safety profile, highlighted in this publication are encouraging.

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Research, United European Gastroenterology, American College, NLRX1, UC, D&O, Biomarker, NEXUS, ACG, Wind, American College of Gastroenterology, D, Poster, Ulcerative colitis, Inflammatory bowel disease, LTE, UZ Leuven, KU Leuven, Pharmacokinetics, Clinical trial, Epithelium, Ulcer, Safety, Patient, Gene expression, Pharmaceutical industry

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.
  • NEXUS Phase 2 proof-of-concept clinical trial:
    The NEXUS trial of NX-13 remains on track as the Company continues to recruit, screen and randomize patients for the trial.
  • Research and development expenses were $3.1 million for the third quarter of 2023, compared to $4.9 million for the third quarter of 2022.
  • General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.0 million for the third quarter of 2022.